Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil in Japanese Subjects With HFrEF
NCT02695420Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Cytokinetics. Started Apr 2016; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02695420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695420.